Literature DB >> 35838759

Progranulin, a moderator of estrogen/estrogen receptor α binding, regulates bone homeostasis through PERK/p-eIF2 signaling pathway.

Yuyou Yang1, Naibo Feng1, Li Liang1, Rong Jiang2, Yiming Pan1, Nana Geng1, Mengtian Fan1, Xiaoli Li1, Fengjin Guo3.   

Abstract

Under normal conditions, the human body employs the synergistic action of osteoblasts and osteoclasts to maintain a dynamic balance between bone formation and resorption. Bone homeostasis plays a very important role in the process of bone formation. Various bone diseases can occur if bone homeostasis is disrupted. In this study, the serum estrogen levels were significantly increased in the granulin (GRN)-deficient mice and PGRN regulates the binding of estrogen and estrogen receptor α (ERα) and then affects estrogen's ability to regulate bone formation and resorption. In addition, this study also explored the role that PGRN plays in regulating bone homeostasis by affecting the binding of estrogen and estrogen receptors through the protein kinase R-like endoplasmic reticulum kinase/phosphorylation of the eukaryotic initiation factor 2 signaling pathway. In summary, we confirmed the important role of PGRN in regulating the estrogen (E2)/ERα signal in maintaining bone homeostasis. Our findings may provide a new strategy for the treatment of osteoporosis and maintaining bone homeostasis. KEY MESSAGES: PGRN is a molecular regulator of the binding of E2 and ERα signal in maintaining bone homeostasis. PGRN plays in regulating bone homeostasis through the PERK/p-eIF2α signaling pathway. The best therapeutic effect of PGRN in osteoporosis is associated with different concentration of E2.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bone homeostasis; Estrogen; Estrogen receptor α; Progranulin

Mesh:

Substances:

Year:  2022        PMID: 35838759     DOI: 10.1007/s00109-022-02233-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   5.606


  37 in total

1.  Understanding the role of progranulin in Alzheimer's disease.

Authors:  Simon D'Alton; Jada Lewis
Journal:  Nat Med       Date:  2014-10       Impact factor: 53.440

2.  Postmenopausal women with osteoporosis consume high amounts of vegetables but insufficient dairy products and calcium to benefit from their virtues: the CoLaus/OsteoLaus cohort.

Authors:  A Lanyan; P Marques-Vidal; E Gonzalez-Rodriguez; D Hans; O Lamy
Journal:  Osteoporos Int       Date:  2019-12-17       Impact factor: 4.507

Review 3.  Novel Therapies for Postmenopausal Osteoporosis.

Authors:  Leonardo Bandeira; John P Bilezikian
Journal:  Endocrinol Metab Clin North Am       Date:  2016-12-23       Impact factor: 4.741

Review 4.  Clinical Practice. Postmenopausal Osteoporosis.

Authors:  Dennis M Black; Clifford J Rosen
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

Review 5.  Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.

Authors:  Benjamin Z Leder
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 6.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

Review 7.  A broader strategy for osteoporosis interventions.

Authors:  Ian R Reid
Journal:  Nat Rev Endocrinol       Date:  2020-03-17       Impact factor: 43.330

8.  PGRN Is Associated with Late-Onset Alzheimer's Disease: a Case-Control Replication Study and Meta-analysis.

Authors:  Hui-Min Xu; Lin Tan; Yu Wan; Meng-Shan Tan; Wei Zhang; Zhan-Jie Zheng; Ling-Li Kong; Zi-Xuan Wang; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-01-28       Impact factor: 5.590

9.  Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.

Authors:  E Söreskog; I Lindberg; J A Kanis; K E Åkesson; D Willems; M Lorentzon; O Ström; P Berling; F Borgström
Journal:  Osteoporos Int       Date:  2021-01-06       Impact factor: 4.507

10.  Targeting skeletal endothelium to ameliorate bone loss.

Authors:  Ren Xu; Alisha Yallowitz; An Qin; Zhuhao Wu; Dong Yeon Shin; Jung-Min Kim; Shawon Debnath; Gang Ji; Mathias P Bostrom; Xu Yang; Chao Zhang; Han Dong; Pouneh Kermani; Sarfaraz Lalani; Na Li; Yifang Liu; Michael G Poulos; Amanda Wach; Yi Zhang; Kazuki Inoue; Annarita Di Lorenzo; Baohong Zhao; Jason M Butler; Jae-Hyuck Shim; Laurie H Glimcher; Matthew B Greenblatt
Journal:  Nat Med       Date:  2018-05-21       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.